Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Using big data to drive cardiovascular innovations Electronic Health Records & Hospital Information Systems ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by